Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide

Molecular Medicine Reports

Volumn 6, Issue 5, 2012, Pages 1013-1017

  Huang, Tao ^a   Gong, W H ^b   Li, X C ^a   Zou, C P ^a   Jiang, G J ^b   Li, X H ^b   Feng, D P ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Etoposide; Osteosarcoma; Paclitaxel; Thermochemotherapy

Indexed keywords

ETOPOSIDE; FAS ANTIGEN; PACLITAXEL;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HYPERTHERMIC THERAPY; IMMUNOCYTOCHEMISTRY; MOLECULAR MECHANICS; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; THERMOCHEMOTHERAPY; UPREGULATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG THERAPY, COMBINATION; ETOPOSIDE; HUMANS; OSTEOSARCOMA; PACLITAXEL; TEMPERATURE;

EID: 84866454932     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1058     Document Type: Article

References (29)

1. Bacci G, Balladelli A, Palmerini E, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience. J Pediatr Hematol Oncol 30: 908-912, 2008.
2. Bacci G, Rocca M, Salone M, et al: High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary andmetastatic lesions. J Surg Oncol 98: 415-420, 2008.
3. Franke M, Hardes J, Helmke K, et al: Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer 56: 771-776, 2011.
4. Andreou D, Bielack SS, Carrle D, et al: The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol 22: 1228-1235, 2011.
5. Routt SM, Zhu J, Zaleski JM and Dynlacht JR: Potentiation of metalloenediyne cytotoxicity by hyperthermia. Int J Hyperthermia 27: 435-444, 2011.
6. Streckfus CF, Brown RE and Bull JM: Proteomics, morphoproteomics, saliva and breast cancer: an emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response. Int J Hyperthermia 26: 649-661, 2010.
7. Trieb K, Blahovec H and Kubista B: Effects of hyperthermia on heat shock protein expression, alkaline phosphatase activity and proliferation in human osteosarcoma cells. Cell Biochem Funct 25: 669-672, 2007. (Pubitemid 351202354)
8. Fan QY, Ma BA, Zhou Y, et al: Bone tumors of the extremities or pelvis treated by microwave-induced hyperthermia. Clin Orthop Relat Res 406: 165-175, 2003. (Pubitemid 36083896)
9. Shido Y, Nishida Y, Suzuki Y, et al: Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model. J Bone Joint Surg Br 92: 580-585, 2010.
10. Vujaskovic Z, Kim DW, Jones E, et al: A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 26: 514-521, 2010.
11. Tang Y and McGoron AJ: Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells. J Photochem Photobiol B 97: 138-144, 2009.
12. Fiorillo A, DeRosa G, Giugliano F, et al: Efficacy of pegylated lyposomal anthracyclines and of intra-arterial carboplatin and doxorubicin combined with local hyperthermia in a case of malignant endovascular papillary angioendothelioma. Curr Drug Deliv 6: 58-61, 2009.
13. Liu B, Yang M, Li X, et al: Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J Pharm Sci 97: 3170-3181, 2008.
14. Michalakis J, Georgatos SD, de Bree E, et al: Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol 14: 1220-1228, 2007.
15. Zoul Z, Filip S, Melichar B, et al: Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy - a pilot experience. Onkologie 27: 385-388, 2004. (Pubitemid 39274236)
16. Mohamed F, Marchettini P, Stuart OA, et al: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 10: 463-468, 2003. (Pubitemid 40486946)
17. de Bree E, Theodoropoulos PA, Rosing H, et al: Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside (Review). Cancer Treat Rev 32: 471-482, 2006. (Pubitemid 44321352)
18. de Bree E, Rosing H, Michalakis J, et al: Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination (Review). Eur J Surg Oncol 32: 666-670, 2006. (Pubitemid 44087882)
19. Miyata S, Takemura G, Kosai K, et al: Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. Am J Pathol 176: 687-698, 2010.
20. Kim HS, Lee YS and Kim DK: Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Pharmacology 84: 300-309, 2009.
21. Li S, Zhou Y, Dong Y and Ip C: Doxorubicin and selenium cooperatively induce Fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res 27: 3075-3082, 2007. (Pubitemid 47607529)
22. Drago-Ferrante R, Santulli A, Di Fiore R, et al: Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1. Int J Oncol 33: 677-687, 2008.
23. Pires NM, Eefting D, de Vries MR, et al: Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 93: 922-927, 2007. (Pubitemid 47122040)
24. Stumm S, Meyer A, Lindner M, et al: Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology 66: 101-111, 2004. (Pubitemid 38608376)
25. Huisman C, Ferreira CG, Bröker LE, et al: Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 8: 596-606, 2002. (Pubitemid 34193982)
26. Wang X, Gao XH, Li X, et al: Local hyperthermia induces apoptosis of keratinocytes in both normal skin and condyloma acuminata via different pathways. Apoptosis 14: 721-728, 2009.
27. Yu DY, Matsuya Y, Zhao QL, et al: Enhancement of hyperthermia-induced apoptosis by a new synthesized class of furan-fused tetracyclic compounds. Apoptosis 12: 1523-1532, 2007. (Pubitemid 46988287)
28. Ohguri T, Imada H, Narisada H, et al: Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. Int J Hyperthermia 25: 160-167, 2009.
29. Hulshof MC, Van Haaren PM, Van Lanschot JJ, et al: Preoperative chemoradiation combined with regional hyperthermia for patients with resectable esophageal cancer. Int J Hyperthermia 25: 79-85, 2009.